EBCTCG
Early Breast Cancer Trialists' Collaborative Group overviews of randomised trials of adjuvant therapy
Phase meta-analysis
- Population
- Women with early breast cancer in randomised trials of adjuvant systemic treatment or radiotherapy; populations differ by paper and are stated per result.
- Design
- Patient-level meta-analyses of randomised trials. Papers covered: tamoxifen (1998), polychemotherapy (1998), chemotherapy and hormonal therapy with 15-year survival (2005), radiotherapy and extent of surgery (2005), tamoxifen by receptor status (2011), radiotherapy after breast-conserving surgery (2011). Each overview has its own trial set; results below are selected values from named papers.
- Arms
- Allocated treatment (experimental): Adjuvant treatment under study in the paper (tamoxifen, chemotherapy or radiotherapy)
- Control (control): No such treatment
- People
- Early Breast Cancer Trialists' Collaborative Group, Early Breast Cancer Trialists' Collaborative Group
Δ 120-month OS+10.9 pointsΔ 120-month OS+5.6 pointsΔ Any first recurrence−15.7 pointsΔ Breast cancer mortality−3.8 points
Show the numbers
| Endpoint | Analysis | Allocated treatment | Control | Effect |
|---|---|---|---|---|
| OSNode-positive women in trials of about 5 years of tamoxifen; analyses restricted to ER-positive or untested tumours10-year survival, tamoxifen versus no tamoxifen | primaryEarly 1998 | 61.4% at 10 y | 50.5% at 10 y | P=2p<0.00001 |
| OSNode-negative women in trials of about 5 years of tamoxifen; analyses restricted to ER-positive or untested tumours10-year survival, tamoxifen versus no tamoxifen | primaryEarly 1998 | 78.9% at 10 y | 73.3% at 10 y | P=2p<0.00001 |
| Any first recurrence10,801 women in 17 randomised trials of radiotherapy versus none after breast-conserving surgery10-year risk of any (locoregional or distant) first recurrence | primaryEarly 2011 | 19.3% | 35% | P=2p<0.00001 |
| Breast cancer mortality10,801 women in 17 randomised trials of radiotherapy versus none after breast-conserving surgery15-year risk of breast cancer death | primaryEarly 2011 | 21.4% | 25.2% | P=2p=0.00005 |
| Endpoint | Analysis | Allocated treatment | Control | Effect |
|---|---|---|---|---|
| OSNode-positive women in trials of about 5 years of tamoxifen; analyses restricted to ER-positive or untested tumours10-year survival, tamoxifen versus no tamoxifen | primaryEarly 1998 | 61.4% at 10 y | 50.5% at 10 y | P=2p<0.00001 |
| OSNode-negative women in trials of about 5 years of tamoxifen; analyses restricted to ER-positive or untested tumours10-year survival, tamoxifen versus no tamoxifen | primaryEarly 1998 | 78.9% at 10 y | 73.3% at 10 y | P=2p<0.00001 |
| Any first recurrence10,801 women in 17 randomised trials of radiotherapy versus none after breast-conserving surgery10-year risk of any (locoregional or distant) first recurrence | primaryEarly 2011 | 19.3% | 35% | P=2p<0.00001 |
| Breast cancer mortality10,801 women in 17 randomised trials of radiotherapy versus none after breast-conserving surgery15-year risk of breast cancer death | primaryEarly 2011 | 21.4% | 25.2% | P=2p=0.00005 |
Appears in
Sources
Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451-67.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707-16.